Core Insights - CNSide Diagnostics, LLC has signed a national agreement with UnitedHealthcare Insurance Company, covering over 51 million people in the U.S. for the CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test [1] Company Overview - CNSide Diagnostics, LLC is a subsidiary of Plus Therapeutics, Inc., focused on developing proprietary laboratory-developed tests to identify tumor cells in patients with carcinomas and melanomas [4] - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, developing targeted radiotherapeutics for challenging cancers of the central nervous system [5] Product Details - The CNSide CSF Assay Platform supports rapid diagnoses, treatment monitoring, and guidance for patients with leptomeningeal metastases, demonstrating superior clinical utility over standard care [2] - More than 11,000 CNSide tests have been performed at over 120 U.S. cancer institutions since 2020, achieving high sensitivity of 92% and specificity of 95%, influencing treatment decisions in 90% of cases [3] Market Impact - The agreement with UnitedHealthcare is expected to enhance the accessibility of the CNSide CSF Assay, potentially increasing its market penetration and utilization among healthcare professionals [1][2]

Core Insights - Plus Therapeutics, Inc. is set to launch its CNSide cerebrospinal fluid (CSF) assay platform and testing services in Texas by August 2025, focusing initially on NCI-Designated Cancer Centers and large private healthcare systems [2][9] - The CNSide assay is designed to diagnose and monitor leptomeningeal metastases (LM), a severe complication of advanced cancer, with a high sensitivity of 92% and specificity of 95% [6][7] - The company has conducted over 11,000 CNSide tests at more than 200 U.S. cancer institutions since 2020, demonstrating significant clinical utility and influencing treatment decisions in over 90% of cases [6][8] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, focusing on developing targeted radiotherapeutics for difficult-to-treat CNS cancers [9] - CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, develops proprietary laboratory tests to identify tumor cells that have metastasized to the CNS [8] - The CNSide CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA, improving patient management for those with LM [8] Market Context - Leptomeningeal metastases occur in approximately 5% of patients with metastatic cancer, with median survival typically ranging from 2 to 6 months, indicating a critical need for effective diagnostic tools and therapies [7] - The current standard of care, CSF cytology, has suboptimal sensitivity, leading to missed or delayed diagnoses, which CNSide aims to address with its advanced testing capabilities [6][5]